open access

Vol 55, No 2 (2017)
Original paper
Submitted: 2017-03-21
Accepted: 2017-06-07
Published online: 2017-06-12
Get Citation

Cardiomyocyte marker expression in dogs with left atrial enlargement due to dilated cardiomyopathy or myxomatous mitral valve disease

Izabela Janus1, Malgorzata Kandefer-Gola, Rafal Ciaputa, Agnieszka Noszczyk-Nowak, Urszula Paslawska, Massimiliano Tursi, Marcin Nowak
DOI: 10.5603/FHC.a2017.0009
·
Pubmed: 28612341
·
Folia Histochem Cytobiol 2017;55(2):52-61.
Affiliations
  1. Division of Pathomorphology and Veterinary Forensics, Department of Pathology, Wroclaw University of Environmental and Life Sciences, Wroclaw, Poland, Poland

open access

Vol 55, No 2 (2017)
ORIGINAL PAPERS
Submitted: 2017-03-21
Accepted: 2017-06-07
Published online: 2017-06-12

Abstract

Introduction. Dilated cardiomyopathy (DCM) and myxomatous mitral valve disease (MMVD) are common heart conditions in dogs. They have different etiology and pathogenesis and although other studies focused on changes in the left ventricles of the affected hearts, the aim of our study was to assess the expressions of some intrinsic proteins in the enlarged left atria.

Material and methods. We performed an immunohistochemical analysis of left atrial specimens obtained from 15 dogs with DCM, 35 dogs with MMVD and six control dogs. We assessed the expression of following proteins: SERCA1, SERCA2, sarcomeric actinin, smooth muscle actin, and dystrophin.

Results. We noted a higher percentage of SERCA1-positive cells in the MMVD group and lower percentage of dystrophin-positive cells in the DCM group as compared to control group. The expression of other proteins was similar in the hearts of control dogs and dogs with heart diseases.

Conclusions. The observed changes in the expression patterns of some proteins in the atria of dogs with DCM and MMVD suggest that atrial enlargement relies not only on volume overload, but also alterations of the intrinsic proteins can contribute to the pathogenesis of dilated cardiomyopathy.  

Abstract

Introduction. Dilated cardiomyopathy (DCM) and myxomatous mitral valve disease (MMVD) are common heart conditions in dogs. They have different etiology and pathogenesis and although other studies focused on changes in the left ventricles of the affected hearts, the aim of our study was to assess the expressions of some intrinsic proteins in the enlarged left atria.

Material and methods. We performed an immunohistochemical analysis of left atrial specimens obtained from 15 dogs with DCM, 35 dogs with MMVD and six control dogs. We assessed the expression of following proteins: SERCA1, SERCA2, sarcomeric actinin, smooth muscle actin, and dystrophin.

Results. We noted a higher percentage of SERCA1-positive cells in the MMVD group and lower percentage of dystrophin-positive cells in the DCM group as compared to control group. The expression of other proteins was similar in the hearts of control dogs and dogs with heart diseases.

Conclusions. The observed changes in the expression patterns of some proteins in the atria of dogs with DCM and MMVD suggest that atrial enlargement relies not only on volume overload, but also alterations of the intrinsic proteins can contribute to the pathogenesis of dilated cardiomyopathy.  

Get Citation

Keywords

dog; heart failure; dilated cardiomyopathy; myxomatous mitral valve disease; left atrium; dystrophin; SERCA1; IHC

About this article
Title

Cardiomyocyte marker expression in dogs with left atrial enlargement due to dilated cardiomyopathy or myxomatous mitral valve disease

Journal

Folia Histochemica et Cytobiologica

Issue

Vol 55, No 2 (2017)

Article type

Original paper

Pages

52-61

Published online

2017-06-12

DOI

10.5603/FHC.a2017.0009

Pubmed

28612341

Bibliographic record

Folia Histochem Cytobiol 2017;55(2):52-61.

Keywords

dog
heart failure
dilated cardiomyopathy
myxomatous mitral valve disease
left atrium
dystrophin
SERCA1
IHC

Authors

Izabela Janus
Malgorzata Kandefer-Gola
Rafal Ciaputa
Agnieszka Noszczyk-Nowak
Urszula Paslawska
Massimiliano Tursi
Marcin Nowak

References (29)
  1. Borgarelli M, Savarino P, Crosara S, et al. Survival characteristics and prognostic variables of dogs with mitral regurgitation attributable to myxomatous valve disease. J Vet Intern Med. 2008; 22(1): 120–128.
  2. Dukes-McEwan J, Borgarelli M, Tidholm A, et al. ESVC Taskforce for Canine Dilated Cardiomyopathy. Proposed guidelines for the diagnosis of canine idiopathic dilated cardiomyopathy. J Vet Cardiol. 2003; 5(2): 7–19.
  3. Häggström J, Duelund Pedersen H, Kvart C. New insights into degenerative mitral valve disease in dogs. Vet Clin North Am Small Anim Pract. 2004; 34(5): 1209–26, vii.
  4. Tidholm A, Häggström J, Borgarelli M, et al. Canine idiopathic dilated cardiomyopathy. Part I: Aetiology, clinical characteristics, epidemiology and pathology. Vet J. 2001; 162(2): 92–107.
  5. Fox PR. Pathology of myxomatous mitral valve disease in the dog. J Vet Cardiol. 2012; 14(1): 103–126.
  6. Hanna N, Cardin S, Leung TK, et al. Differences in atrial versus ventricular remodeling in dogs with ventricular tachypacing-induced congestive heart failure. Cardiovasc Res. 2004; 63(2): 236–244.
  7. Janus I, Nowak M, Madej J. Pathomorphological changes of the myocardium in canine dilated cardiomyopathy (DCM). Bull Vet Inst Pulawy. 2015; 59(1): 135–142.
  8. Hein S, Kostin S, Heling A, et al. The role of the cytoskeleton in heart failure. Cardiovasc Res. 2000; 45(2): 273–278.
  9. Schaper J, Kostin S, Hein S, et al. Structural remodelling in heart failure. Exp Clin Cardiol. 2002; 7(2-3): 64–68.
  10. Sharov VG, Kostin S, Todor A, et al. Expression of cytoskeletal, linkage and extracellular proteins in failing dog myocardium. Heart Fail Rev. 2005; 10(4): 297–303.
  11. Janus I, Kandefer-Gola M, Ciaputa R, et al. The immunohistochemical evaluation of selected markers in the left atrium of dogs with end-stage dilated cardiomyopathy and myxomatous mitral valve disease – a preliminary study. Ir Vet J. 2016; 69: 18.
  12. Janus I, Noszczyk-Nowak A, Nowak M, et al. A comparison of the histopathologic pattern of the left atrium in canine dilated cardiomyopathy and chronic mitral valve disease. BMC Vet Res. 2016; 12: 3.
  13. Hanna N, Cardin S, Leung TK, et al. Differences in atrial versus ventricular remodeling in dogs with ventricular tachypacing-induced congestive heart failure. Cardiovasc Res. 2004; 63(2): 236–244.
  14. Periasamy M, Bhupathy P, Babu GJ. Regulation of sarcoplasmic reticulum Ca2+ ATPase pump expression and its relevance to cardiac muscle physiology and pathology. Cardiovasc Res. 2008; 77(2): 265–273.
  15. Sumbilla C, Cavagna M, Zhong L, et al. Comparison of SERCA1 and SERCA2a expressed in COS-1 cells and cardiac myocytes. Am J Physiol. 1999; 277(6 Pt 2): H2381–H2391.
  16. Summerfield N, Peters ME, Hercock CA, et al. Immunohistochemical evidence for expression of fast-twitch type sarco(endo)plasmic reticulum Ca2+ ATPase (SERCA1) in German shepherd dogs with dilated cardiomyopathy myocardium. J Vet Cardiol. 2010; 12(1): 17–23.
  17. Driesen RB, Verheyen FK, Debie W, et al. Re-expression of alpha skeletal actin as a marker for dedifferentiation in cardiac pathologies. J Cell Mol Med. 2009; 13(5): 896–908.
  18. Gofflot S, Kischel P, Thielen C, et al. Characterization of an antibody panel for immunohistochemical analysis of canine muscle cells. Vet Immunol Immunopathol. 2008; 125(3-4): 225–233.
  19. Branishte TA, Dudnakova TV, Dergilev KV, et al. [Expression of contractile and cytoskeletal proteins in myocardium of patients with dilated cardiomyopathy]. Kardiologiia. 2004; 44(12): 31–36.
  20. Kamdar F, Garry DJ. Dystrophin-deficient cardiomyopathy. J Am Coll Cardiol. 2016; 67(21): 2533–2546.
  21. Fine DM, Shin JH, Yue Y, et al. Age-matched comparison reveals early electrocardiography and echocardiography changes in dystrophin-deficient dogs. Neuromuscul Disord. 2011; 21(7): 453–461.
  22. Nakamura A. X-Linked dilated cardiomyopathy: a cardiospecific phenotype of dystrophinopathy. Pharmaceuticals (Basel). 2015; 8(2): 303–320.
  23. Armstrong SC, Latham CA, Shivell CL, et al. Ischemic loss of sarcolemmal dystrophin and spectrin: correlation with myocardial injury. J Mol Cell Cardiol. 2001; 33(6): 1165–1179.
  24. Rodríguez M, Cai WJ, Kostin S, et al. Ischemia depletes dystrophin and inhibits protein synthesis in the canine heart: mechanisms of myocardial ischemic injury. J Mol Cell Cardiol. 2005; 38(5): 723–733.
  25. Tidholm A, Jönsson L. Histologic characterization of canine dilated cardiomyopathy. Vet Pathol. 2005; 42(1): 1–8.
  26. Whitney JC. Cardiovascular pathology. J Small Anim Pract. 1967; 8(8): 459–465.
  27. Atkins C, Bonagura J, Ettinger S, et al. Guidelines for the diagnosis and treatment of canine chronic valvular heart disease. J Vet Intern Med. 2009; 23(6): 1142–1150.
  28. Spier AW, Meurs KM, Coovert DD, et al. Use of western immunoblot for evaluation of myocardial dystrophin, alpha-sarcoglycan, and beta-dystroglycan in dogs with idiopathic dilated cardiomyopathy. Am J Vet Res. 2001; 62(1): 67–71.
  29. The Polish Parliament (Sejm) [Internet]. Warsaw: The Polish Parliament: Act on the protection of animals used for scientific or educational purposes; c2015. http://orka.sejm.gov.pl/proc7.nsf/ustawy/2709_u.htm. (2017 March 28).

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl